TICKERNERD
Menu
MXCTMXCTHealthcare · Medical Devices

MXCT Stock Forecast: MaxCyte, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$1.38
0.00% on the day

The 6 Wall Street analysts covering MaxCyte, Inc. hold a median 12-month price target of $4.5 — +226.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 72 of 100 as at 22 Aug 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$142.4M
Ticker Nerd rank
72 / 100
Median analyst target
$4.50
Analysts covering
6
Total return, dividends reinvested
1W
+4.5%
1M
+12.2%
YTD
−11.0%
1Y
−2.8%
From 52W high
−24.6%
From 52W low
+104.1%
$0.68
$1.83
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MXCT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores MaxCyte, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
72 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
89
Issuance
81
Accruals
77
Size
71
Revisions
49
Value
48
Quality
48
Volatility
46
Momentum
30

Growth (89): Sales and profits are climbing, and climbing faster than before.

Momentum (30): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MXCT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MXCT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00$5.00Oct 25Jan 26Apr 26Jul 26MXCTHigh $5.00Median $4.50Low $2.43

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says6 analysts
5 Buy1 Hold0 Sell
Low $2.43Median $4.50High $5.00

The green dot is the last close — the median target sits +226.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
25 Mar 2026Craig-HallumMaintainsBuy$7.00 → $5.00
11 Aug 2025BTIGDowngradeNeutral—
7 Aug 2025William BlairDowngradeMarket Perform—
22 July 2025Stephens & Co.AssumesOverweight$6.00
12 Mar 2025StifelMaintainsBuy—
23 Apr 2024Stephens & Co.ReiteratesOverweight—
13 Mar 2024BTIGMaintainsBuy—
13 Mar 2024Stephens & Co.ReiteratesOverweight—
29 Nov 2023Craig-HallumInitiatesBuy—
5 Oct 2023Stephens & Co.ReiteratesOverweight—
28 Mar 2023Stephens & Co.ReiteratesOverweight—
15 Aug 2022BTIGMaintainsBuy—
24 Aug 2021BTIGInitiatesBuy—
24 Aug 2021Cowen & Co.InitiatesOutperform—
24 Aug 2021Stephens & Co.InitiatesOverweight—
24 Aug 2021StifelInitiatesBuy—
24 Aug 2021William BlairInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MXCT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

MXCT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

MaxCyte, Inc. (MXCT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.3×

Cheaper than 88% of US stocks

Price / sales
4.6×

Cheaper than 28% of US stocks

Price / book
0.9×

Cheaper than 76% of US stocks

EV / EBITDA
−1.8×

Cheaper than 70% of US stocks

Growth & margins
Revenue growth (YoY)
−14.5%

Higher than 13% of US stocks

Earnings growth (YoY)
−7.1%

Higher than 28% of US stocks

Gross margin
83.7%

Higher than 93% of US stocks

Operating margin
−140.7%

Higher than 12% of US stocks

Net margin
−114.8%

Higher than 5% of US stocks

Returns & dividend
Return on equity
−20.4%

Higher than 31% of US stocks

Return on assets
−10.6%

Higher than 26% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

MXCT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
MXCTMaxCyte, Inc.$142.4M
72
OWLTOwlet, Inc.$150.8M
34
INGNInogen, Inc.$152.8M
86
QTRXQuanterix Corp.$140.8M
28
APYXApyx Medical Corp.$128.0M
70
QSIQuantum-Si, Inc.$179.9M
31
LUCDLucid Diagnostics, Inc.$195.8M
45

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own MaxCyte, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MXCT news & analysis

MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies

GlobeNewsWire · 19 Aug 2026positive

MaxCyte announced the launch of CHANGE-seq-BE™ and ONE-seq-BE™ off-target nomination assays, available through its SeQure™ service. The assays are designed to provide sensitive identification of off-target sites for adenine and cytosine base editors in genome editing characterization.

Why it matters — The launch expands MaxCyte's SeQure™ service offering by addressing a key gap in genome editing off-target assessment, potentially strengthening its platform for cell therapy development.

MaxCyte Q2 Earnings Call Highlights

MarketBeat · 13 Aug 2026neutral

MaxCyte reported second-quarter 2026 revenue of $7.3 million, down 15% from $8.5 million a year earlier, due to lower license revenue, instrument placement timing, and prior-year processing assembly purchases. Management said the quarter exceeded its expectations and represented progress toward stabilizing the business before returning to growth in the second half of the year.

Why it matters — The revenue decline and management's outlook on stabilization and second-half growth are directly relevant to MXCT watchers tracking the company's near-term trajectory.

MaxCyte, Inc. (MXCT) Q2 2026 Earnings Call Transcript

Seeking Alpha · 13 Aug 2026neutral

MaxCyte, Inc. held its Q2 2026 earnings call, during which management discussed the company's financial results and operational performance for the quarter.

Why it matters — This earnings call provides MXCT investors and analysts with direct commentary from management on the company's recent financial health and strategic direction.

MaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue Estimates

Zacks Investment Research · 12 Aug 2026positive

MaxCyte, Inc. reported a second-quarter loss of $0.08 per share, smaller than the Zacks Consensus Estimate of a $0.12 loss and an improvement from the $0.12 loss per share in the prior-year quarter. The company also beat revenue estimates.

Why it matters — A narrower-than-expected loss and revenue beat indicate the company's quarterly performance came in better than analysts had projected.

MaxCyte Reports Second Quarter 2026 Financial Results

GlobeNewsWire · 12 Aug 2026positive

MaxCyte reported second-quarter 2026 financial results with total revenue of $7.3 million, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue, and reiterated its full-year 2026 guidance. The company also repurchased approximately $5.5 million of common stock to date under its $10 million share repurchase program and, after the quarter ended, announced a strategic, multi-platform technology license partnership with Genentech in July.

Why it matters — A MaxCyte watcher would care because the report covers key revenue figures, an affirmed full-year outlook, ongoing share repurchases, and a newly announced strategic licensing partnership with Genentech.

FAQ

Frequently asked questions about MXCT stock

What is the MXCT stock price forecast for 2026-2027?

The 6 Wall Street analysts covering MaxCyte, Inc. have a median 12-month price target of $4.5, with estimates ranging from $2.43 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MXCT stock a buy right now?

Of the 6 analysts covering MaxCyte, Inc., 5 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MaxCyte, Inc. 72 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MXCT?

As at 22 Aug 2026, MaxCyte, Inc. ranks 72 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (89 of 100).

Will MXCT stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +226.1% from the last close, and Ticker Nerd's factor model ranks MaxCyte, Inc. 72 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MXCT stock forecast for 2030?

No analyst covering MaxCyte, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MXCT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.43 to $5 over the next 12 months.

How has MXCT stock performed over the past year?

MaxCyte, Inc. returned -2.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does MaxCyte, Inc. do?

MaxCyte, Inc. is a commercial cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics.

What is the latest news on MXCT?

The most recent item we track (GlobeNewsWire, 19 Aug 2026): "MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies". MaxCyte announced the launch of CHANGE-seq-BE™ and ONE-seq-BE™ off-target nomination assays, available through its SeQure™ service. The assays are designed to provide sensitive identification of off-target sites for adenine and cytosine base editors in genome editing characterization.

Company

About MaxCyte, Inc.

MaxCyte, Inc. is a commercial cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics. Its proprietary Flow Electroporation platform and ExPERT instrument portfolio, including ExPERT ATx for small to medium scale transfection, ExPERT STx for protein production and drug development, ExPERT GTx for large scale therapeutic applications, and ExPERT VLx for very large volume cell-engineering, deliver high transfection efficiency, cell viability, and scalability. The company also offers disposable processing assemblies, electroporation buffers, software protocols, and SeQure DX services for on-target and off-target editing assessments. MaxCyte generates revenue through sales of instruments, consumables, licenses, and its Strategic Platform License program, which grants partners non-exclusive rights for research, clinical, and commercial use, including milestone payments and royalties. These technologies support diverse cell types and payloads in cell and gene therapies for cancer, autoimmune diseases, and other areas, serving pharmaceutical and biotechnology companies worldwide. Founded in 1998 and headquartered in Rockville, Maryland, MaxCyte plays a key role in the biotechnology sector by facilitating precise, efficient, and GMP-ready cell engineering.

CEO Mr. Maher Masoud · 114 employees · United States · https://www.maxcyte.com